Cellectar Biosciences Q3 2026 earnings

CLRB · 2026-11-10 07:25 BMO ET · 8-K on SEC · 10-Q on SEC

Operating expenses increased 34% YoY to $8.1M, and the net loss widened to $7.97M despite a $50K warrant loss reversal.

Headline numbers

not stated in the 8-K

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $8.1M (+67% YoY)
  • One-offs in the quarter Warrant loss reversal ($50K)
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge not stated in the 8-K

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$24.58M$33.99M$13.20M-28%
Total current assets$25.71M$34.88M$14.04M-26%
Total assets$29.74M$36.64M$14.98M-19%

Guidance

not stated in the 8-K

What drove it

  • Revenue story No revenue reported.
  • EPS story Net loss per share widened due to higher operating expenses and a warrant loss reversal, partially offset by higher interest income.
  • One-off check Warrant loss reversal of $50K (vs $294K gain in prior year).

The good

  • Interest income increased 59% YoY to $179K.

The bad

  • Research and development expenses increased 115% YoY to $5.44M.
  • Net loss widened 44% YoY to $7.97M.
  • Cash and cash equivalents declined 28% QoQ to $24.58M.

The ugly

  • none

Open questions

  • What drove the 115% YoY increase in R&D expenses?
  • What is the specific use of the $2.28M contracted research organization deposit?
Full release

Cellectar Biosciences (CLRB) earnings release, November 10, 2026

Cellectar Biosciences, Inc. (CLRB) · Form 8-K, Item 2.02 · Filed · SEC filing

Cellectar Biosciences

Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

Presented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in

Waldenström macroglobulinemia (WM)

On track to dose first patients in the confirmatory Phase 3 trial of iopofosine I 131 in first quarter 2027 and to file for accelerated approval with the FDA in 1H 2027

Published case study of iopofosine I 131 highlighting a complete response lasting more than eight years in heavily pretreated diffuse large B-cell lymphoma patient

Company to host webcast and conference call at 8:30 AM ET today

FLORHAM PARK, N.J., November 10,

2026 (GLOBE NEWSWIRE)

-- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, today announced financial results for the quarter ended September 30, 2026, and provided a corporate update.

“We remain focused on executing the clinical, regulatory and operational activities necessary to position iopofosine I 131 for potential registration and commercialization in Waldenström macroglobulinemia, and we believe our third quarter progress represents a significant step toward that goal,” said James Caruso, president and chief executive officer of Cellectar Biosciences. “The new sub-analysis efficacy data presented at the International Workshop for Waldenström Macroglobulinemia (IWWM) further strengthen our confidence in the clinical profile of iopofosine I 131, demonstrating high response rates, durable outcomes and a favorable safety profile in a difficult-to-treat post-BTK inhibitor patient population, which is the same patient population being evaluated in our Phase 3 confirmatory clinical trial.”

“To further maximize the long-term value of the program, we have initiated our Phase 1b dosimetry trial, which we believe offers an important opportunity to further characterize iopofosine I 131 across WM treatment settings, including first and second line. With these trials underway, a planned NDA submission in the first half of 2027, and continued advancement of our broader PDC pipeline, we believe Cellectar is entering a period of significant value creation with multiple meaningful milestones in 2027,” continued Mr. Caruso.

Third Quarter 2026 and Recent Corporate

Highlights

2026 Financial Highlights

Conference Call & Webcast

Details

Cellectar management will host a conference call and webcast today, November 10, 2026, at 8:30 AM Eastern Time to discuss these results and answer questions. Stockholders and other interested parties may participate in the conference call by dialing 1-800-717-1738. A live webcast of the conference call can be accessed in the “Events & Presentations” section of Cellectar’s website at www.cellectar.com. A recording of the webcast will be available and archived on the Company’s website for approximately 90 days.

About Cellectar Biosciences, Inc.

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug

Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.

The company’s product pipeline includes iopofosine I 131, which is a PDC designed to provide targeted delivery of iodine-131 (radioisotope). Iopofosine I 131 has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström Macroglobulinemia (WM), in relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma. The CLOVER-2 Phase 1b trial is evaluating iopofosine I 131 in pediatric patients with high-grade gliomas. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two

Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation.

Cellectar is also developing CLR 121125

(CLR 125), an iodine-125 Auger-emitting program targeted for solid tumors, such as triple negative breast (TNBC), lung, and colorectal cancer, and is currently being evaluated in a Phase 1b trial for TNBC, which will determine the recommended dose for the subsequent Phase

2 trial. CLR 125 has been well tolerated in vivo and has demonstrated strong preclinical data showing reduction or inhibition of solid tumor growth.

In addition to these assets, the Cellectar team is developing CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors in indications with significant unmet need, such as pancreatic cancer, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

For more information, please visit https://www.cellectar.com/ or join the conversation by liking and following us on the company’s social media channels:

X,

LinkedIn, and

Facebook.

Forward Looking Statements Disclaimer

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
OPERATING EXPENSES:
Research and development5,435,7962,523,30513,000,4088,340,200
General and administrative2,668,2192,327,3918,093,5608,949,015
Total operating expenses8,104,0154,850,69621,093,96817,289,215
LOSS FROM OPERATIONS-8,104,015-4,850,696-21,093,968-17,289,215
OTHER INCOME (EXPENSE):
Gain (loss) on valuation of warrants-50,000294,276159,000455,874
Interest income179,272112,543375,627337,525
Total other income129,272406,819534,627793,399
NET LOSS-7,974,743-4,443,877-20,559,341-16,495,816
NET LOSS PER SHARE — BASIC & DILUTED-0.46-1.41-1.81-7.82
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING — BASIC & DILUTED17,462,8983,162,04011,360,0542,108,234

Balance Sheet

September 30, — (Unaudited)

September 30, – 2026December 31, – 2025
CURRENT ASSETS:
Cash and cash equivalents24,582,11513,196,033
Prepaid expenses and other current assets1,130,854842,432
Total current assets25,712,96914,038,465
Property, plant & equipment, net268,905549,405
Operating lease right-of-use asset1,384,274360,671
Contracted research organization deposit2,282,595
Other long-term assets94,52029,780
TOTAL ASSETS29,743,26314,978,321
CURRENT LIABILITIES:
Accounts payable and accrued liabilities5,729,3024,423,548
Warrant liability67,000226,000
Lease liability, current1,318100,189
Total current liabilities5,797,6204,749,737
Lease liability, net of current portion1,530,277309,397
TOTAL LIABILITIES7,327,8975,059,134
MEZZANINE EQUITY:
Series D preferred stock, 111.11 shares authorized, 0.00 and 111.11 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively1,382,023
STOCKHOLDERS’ EQUITY:
Series E-2 preferred stock, 1,225 shares authorized; 0.00 and 35.60 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively520,778
Common stock, $0.00001 par value; 170,000,000 shares authorized; 10,039,183 and 4,240,129 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively10042
Additional paid-in capital312,108,109277,149,844
Accumulated deficit-289,692,843-269,133,500
Total stockholders’ equity22,415,3668,537,164
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY29,743,26314,978,321

Cash Flow

From the 10-Q · Nine Months Ended — (UNAUDITED)

Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss-20,559,341-16,495,816
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization-39,225164,136
Stock-based compensation expense1,398,4481,695,916
Change in operating lease right-of-use asset95,63656,033
Change in fair value of warrants-159,000-455,874
Changes in:
Prepaid expenses and other current assets34,680-105,744
Lease liability2,770-62,074
Accounts payable and accrued liabilities1,305,754-3,570,658
Other assets-2,347,336
Cash used in operating activities-20,267,614-18,774,081
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant & equipment-3,378
Cash used in investing activities-3,378
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants, net of issuance costs (Note 2)72,251,380
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs (Note 2)31,657,0675,788,380
Issuance of common stock in connection with exercise of pre-funded warrants3
Cash provided by financing activities31,657,0748,039,763
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS11,386,082-10,734,318
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD13,196,03323,288,607
CASH AND CASH EQUIVALENTS AT END OF PERIOD24,582,11512,554,289
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Conversion of preferred stock to common stock1,902,801$—
Value of warrants issued to placement agent1,473,793$—
Right of use asset obtained in exchange for operating lease liability1,119,239$—
Settlement of warrants to equity$—462,760

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may,"

"expect," "believe," "anticipate," "intend," "could," "estimate," "continue,"

"plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements... (truncated) future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31,

2025, and our Form 10-Q for the quarterly period ended September 30, 2026. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

INVESTORS:

Anne Marie Fields

Precision AQ

212-362-1200 annemarie.fields@precisionaq.com

+++ TABLES FOLLOW

+++

CELLECTAR BIOSCIENCES, INC.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.